# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Ovarian cancer

Cancer, Ovarian
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 2501-2510 of 2727 results.
Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer
Status: Active, not recruiting
Last Changed: Oct 22, 2020
First Received: Jan 12, 2017
Disease(s): FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 3 Endometrial Endometrioid Adenocarcinoma
Intervention(s): Entinostat, Hysterectomy, Laboratory Biomarker Analysis, Medroxyprogesterone Acetate
Locations: CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, Arkansas, United States
John Muir Medical Center-Concord Campus, Concord, California, United States
John Muir Medical Center-Walnut Creek, Walnut Creek, California, United States
Rocky Mountain Cancer Centers-Aurora, Aurora, Colorado, United States
University of Colorado Hospital, Aurora, Colorado, United States
... and 230 other locations.
International PPB/DICER1 Registry
Status: Recruiting
Last Changed: Aug 19, 2019
First Received: Dec 22, 2017
Disease(s): Pleuropulmonary Blastoma, Sertoli-Leydig Cell Tumor, DICER1 Syndrome, Cystic Nephroma, Wilms Tumor, Pineoblastoma, Renal Sarcoma, Nodular Hyperplasia of Thyroid, Nasal Chondromesenchymal Hamartoma, Ciliary Body Medulloepithelioma, Neuroblastoma, Pituitary Cancer, Embryonal Rhabdomyosarcoma
Locations: Children's Minnesota, Minneapolis, Minnesota, United States
Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer
Status: Active, not recruiting
Last Changed: Sep 09, 2020
First Received: Apr 05, 2016
Disease(s): Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Metastatic Endometrioid Adenocarcinoma, Recurrent Uterine Corpus Carcinoma
Intervention(s): Copanlisib, Laboratory Biomarker Analysis
Locations: Yale University, New Haven, Connecticut, United States
UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States
University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
Northside Hospital, Atlanta, Georgia, United States
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia, United States
... and 39 other locations.
Evaluation of the Efficacy for Sentinel Lymph Node Policy in Intermediate-risk Endometrial Carcinomas
Status: Withdrawn
Last Changed: Feb 05, 2020
First Received: Sep 19, 2018
Disease(s): Endometrial Endometrioid Adenocarcinoma
Intervention(s): SLN arm
Locations: Obstetrics and Gynecology Hospital, Fudan University, Shanghai, Shanghai, China
A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma
Status: Recruiting
Last Changed: Aug 17, 2020
First Received: Jan 02, 2017
Disease(s): Recurrent Endometrial Carcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Refractory Endometrial Carcinoma, Refractory Endometrial Endometrioid Adenocarcinoma, Stage III Uterine Corpus Cancer AJCC v8, Stage IIIA Uterine Corpus Cancer AJCC v8, Stage IIIB Uterine Corpus Cancer AJCC v8, Stage IIIC Uterine Corpus Cancer AJCC v8, Stage IIIC1 Uterine Corpus Cancer AJCC v8, Stage IIIC2 Uterine Corpus Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8
Intervention(s): Everolimus, Letrozole, Ribociclib
Locations: Lyndon Baines Johnson General Hospital, Houston, Texas, United States
M D Anderson Cancer Center, Houston, Texas, United States
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
Status: Completed
Last Changed: Mar 05, 2014
First Received: Oct 03, 2007
Disease(s): Cancer
Intervention(s): Fentanyl sublingual spray, Placebo
Locations: InSys Therapeutics, Incorporated, Chandler, Arizona, United States
Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer
Status: Terminated
Last Changed: Aug 16, 2018
First Received: Jul 30, 2009
Disease(s): Cancer
Intervention(s): DNA analysis, polymorphism analysis, laboratory biomarker analysis, medical chart review, questionnaire administration, assessment of therapy complications, evaluation of cancer risk factors
Locations: Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
Status: Completed
Last Changed: Feb 23, 2018
First Received: Sep 28, 2010
Disease(s): Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation, Endometrial Serous Adenocarcinoma, Endometrioid Stromal Sarcoma, Recurrent Uterine Corpus Carcinoma
Intervention(s): Trebananib
Locations: Hartford Hospital, Hartford, Connecticut, United States
The Hospital of Central Connecticut, New Britain, Connecticut, United States
Sarasota Memorial Hospital, Sarasota, Florida, United States
Memorial University Medical Center, Savannah, Georgia, United States
Rush University Medical Center, Chicago, Illinois, United States
... and 29 other locations.
POEM STUDY: A Phase IIa Trial in Endometrial Carcinoma With Temsirolimus
Status: Completed
Last Changed: Apr 14, 2015
First Received: Mar 21, 2014
Disease(s): Carcinoma, Endometrioid, mTOR Protein
Intervention(s): Temsirolimus
Locations: Barcelona, Spain
Madrid, Spain
Valencia, Spain
Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
Status: Completed
Last Changed: Feb 17, 2020
First Received: May 24, 2007
Disease(s): Endometrial Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Serous Adenocarcinoma, Recurrent Uterine Corpus Carcinoma, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7, Uterine Carcinosarcoma, Uterine Corpus Carcinosarcoma
Intervention(s): Sunitinib Malate
Locations: Tower Cancer Research Foundation, Beverly Hills, California, United States
City of Hope Comprehensive Cancer Center, Duarte, California, United States
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
City of Hope South Pasadena, South Pasadena, California, United States
... and 25 other locations.